Quetiapine in relapsing schizophrenia: clinical efficacy and effect on monoaminergic parameters

2003 ◽  
Vol 15 (3) ◽  
pp. 133-139 ◽  
Author(s):  
F. M. M. A. van der Heijden ◽  
W. M. A. Verhoeven ◽  
D. Fekkes ◽  
A. E. S. Sijben ◽  
S. Tuinier
Keyword(s):  
Side Effects ◽  
Treatment Effect ◽  
Biochemical Parameters ◽  
Controlled Trial ◽  
Response To Treatment ◽  
Extrapyramidal Side Effects ◽  
Open Label ◽  
Schizophrenic Patients ◽  
Efficacy Measures ◽  
Efficacy Parameters

Methods:Tolerability, safety and effectiveness of quetiapine in an in-patient group with a relapse of schizophrenia and the possible role of plasma amino acid concentrations, 5-HT parameters and HVA in the prediction of response to treatment were investigated in an open-label baseline-controlled trial of 14 weeks in 21 hospitalized schizophrenic patients. Responders were defined as those patients who exhibit at least a 40% reduction of BPRS total scores. Secondary efficacy measures were the PANSS, the Clinical Global Impression (CGI)-severity scale and the MADRS. Extrapyramidal side-effects were evaluated with the AIMS. Other side-effects were monitored at regular intervals. Amino acids and the derived tryptophan and tyrosine ratios, as well as monoaminergic parameters, were assessed in plasma at baseline and at weeks 3, 6 and 14.Results:Treatment with quetiapine resulted in the predefined treatment effect in 10 out of the 17 patients who completed at least 4 weeks of treatment. Effect in responders was observed on all efficacy parameters, including lower MADRS scores. No extrapyramidal side-effects emerged. Clinical and biochemical parameters did not predict response to treatment.Conclusions:This study demonstrates the moderate antipsychotic efficacy of quetiapine on preferentially positive symptoms in a group of relatively young schizophrenics. Some observed changes in biochemical parameters are discussed.

scholarly journals Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e037306
Author(s):  
Julien Hogan ◽  
Aubriana Perez ◽  
Anne-Laure Sellier-Leclerc ◽  
Isabelle Vrillon ◽  
Francoise Broux ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Side Effects ◽  
Controlled Trial ◽  
Primary Study ◽  
Childhood Onset ◽  
Open Label ◽  
Substantial Impact ◽  
Frequently Relapsing Nephrotic Syndrome ◽  
Steroid Dependent

IntroductionGuidelines for the treatment of steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS) are lacking. Given the substantial impact of SDNS/FRNS on quality of life, strategies aiming to provide long-term remission while minimising treatment side effects are needed. Several studies confirm that rituximab is effective in preventing early relapses in SDNS/FRNS; however, the long-term relapse rate remains high (~70% at 2 years). This trial will assess the association of intravenous immunoglobulins (IVIgs) to rituximab in patients with SDNS/FRNS and inform clinicians on whether IVIg’s immunomodulatory properties can alter the course of the disease and reduce the use of immunosuppressive drugs and their side effects.Methods and analysisWe conduct an open-label multicentre, randomised, parallel group in a 1:1 ratio, controlled, superiority trial to assess the safety and efficacy of a single infusion of rituximab followed by IVIg compared with rituximab alone in childhood-onset FRNS/SDNS. The primary outcome is the occurrence of first relapse within 24 months. Patients are allocated to receive either rituximab alone (375 mg/m²) or rituximab followed by IVIg, which includes an initial Ig dose of 2 g/kg, followed by 1.5 g/kg injections once a month for the following 5 months (maximum dose: 100 g).Ethics and disseminationThe study has been approved by the ethics committee (Comité de Protection des Personnes) of Ouest I and authorised by the French drug regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé). Results of the primary study and the secondary aims will be disseminated through peer-reviewed publications.Trial registration numberNCT03560011.

Neuroleptic Prescription for Chinese Schizophrenics in Hong Kong

1992 ◽  
Vol 26 (2) ◽  
pp. 262-264 ◽  
Author(s):  
Helen Chiu ◽  
Sing Lee ◽  
C.M. Leung ◽  
Y.K. Wing
Keyword(s):  
Hong Kong ◽  
Side Effects ◽  
High Frequency ◽  
Anticholinergic Drugs ◽  
Extrapyramidal Side Effects ◽  
High Potency ◽  
Frequency Of Use ◽  
Daily Dose ◽  
Schizophrenic Patients ◽  
The Mean

There are very few studies on the pattern of neuroleptic prescription for schizophrenics in Asia. 106 schizophrenic patients in a psychiatric unit of a general teaching hospital in Hong Kong were surveyed. The mean daily dose (in chlorpromazine equivalent) was low (568.5mg). The mean daily dose of high potency agents was four times that of low potency agents. A high frequency of use of anticholinergic drugs may indicate that Chinese are more susceptible to acute extrapyramidal side-effects.

scholarly journals Granulocyte Colony-stimulating Factor as Bridging Therapy for Pediatric Decompensated Liver Cirrhosis Prior to Liver Transplantation: an Open-label Randomised Controlled Trial

2021 ◽  
Author(s):  
Tri Hening Rahayatri ◽  
Aria Kekalih ◽  
Alida Harahap ◽  
Aryono Hendarto ◽  
Hanifah Oswari ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Liver Cirrhosis ◽  
Side Effects ◽  
Nutritional Status ◽  
Controlled Trial ◽  
Intervention Group ◽  
Decompensated Cirrhosis ◽  
Open Label ◽  
Decompensated Liver Cirrhosis ◽  
Interventional Group

Abstract Decompensated cirrhosis in children is a leading indication of liver transplantation (LT). Granulocyte-colony stimulating factor (G-CSF) therapy has shown promising results in adult decompensated cirrhosis. Our study aimed to investigate the effect of G-CSF on liver function, Pediatric End-stage liver disease (PELD) score, CD34+ cells mobilization, nutritional status, short-term side effects, and survival in children indicated for liver transplantation (LT).We performed an open-label, randomized controlled trial with decompensated liver cirrhosis between 3 months to 12 years old. The intervention group received a subcutaneous injection of G-CSF (5 μg/kg/day) for twelve courses in addition to standard medical treatment (SMT) for liver cirrhosis. We measured liver function, PELD scores, CD34+ cell mobilization, the change of leucocyte and neutrophil count, nutritional status, side effects, and survival within three months. Thirty-five pediatric patients were randomized into 17 interventional groups and 18 control groups. During the trial, 14 (82%) of the interventional group completed the intervention course. The median age was 18 months in the interventional group and 14.5 months in the control group. The alanine aminotransferase (ALT) level showed significant improvement in the intervention group, while other liver parameters, PELD score, nutritional status, and survival, did not. CD34+ cells mobilization rose in the interventional group but was statistically insignificant. Minor side effects of G-CSF were found in the intervention group.Multiple doses of G-CSF significantly improve ALT but did not improve PELD score, nutritional status, and survival in three months.

Sulpiride: an advance in neuroleptics?

1984 ◽  
Vol 22 (8) ◽  
pp. 31-32
Keyword(s):  
Side Effects ◽  
Social Withdrawal ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients ◽  
Substituted Benzamide ◽  
The Uk

Sulpiride (Dolmatil - Squibb) is a substituted benzamide related to metoclopramide. It has only recently been marketed in the UK, but has been used in Europe for many years. The manufacturer claims that the drug has both antidepressive and neuroleptic properties, and that it is of particular benefit for schizophrenic patients who develop social withdrawal. Extrapyramidal side effects are claimed to be less than with conventional neuroleptics.

scholarly journals Efficacy of Acupuncture versus Combined Oral Contraceptive Pill in Treatment of Moderate-to-Severe Dysmenorrhea: A Randomized Controlled Trial

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Intira Sriprasert ◽  
Suparerk Suerungruang ◽  
Porntip Athilarp ◽  
Anuchart Matanasarawoot ◽  
Supanimit Teekachunhatean
Keyword(s):  
Randomized Controlled Trial ◽  
Oral Contraceptive ◽  
Side Effects ◽  
Controlled Trial ◽  
Oral Contraceptive Pill ◽  
Open Label ◽  
Intention To Treat ◽  
Combined Oral Contraceptive ◽  
Randomized Controlled ◽  
Pain Scores

This open-label randomized controlled trial was designed to compare the efficacy of acupuncture and combined oral contraceptive (COC) pill in treating moderate-to-severe primary dysmenorrhea. Fifty-two participants were randomly assigned to receive either acupuncture (n= 27) or COC (n= 25) for three menstrual cycles. Mefenamic acid was prescribed as a recue analgesic drug with both groups. The statistical approach used for efficacy and safety assessments was intention-to-treat analysis. By the end of the study, both treatments had resulted in significant improvement over baselines in all outcomes, that is, maximal dysmenorrhea pain scores, days suffering from dysmenorrhea, amount of rescue analgesic used, and quality of life assessed by SF-36 questionnaire. Over the three treatment cycles, COC caused greater reduction in maximal pain scores than acupuncture, while improvements in the remaining outcomes were comparable. Responders were defined as participants whose maximal dysmenorrhea pain scores decreased at least 33% below their baseline. Response rates following both interventions at the end of the study were not statistically different. Acupuncture commonly caused minimal local side effects but did not cause any hormone-related side effects as did COC. In conclusion, acupuncture is an alternative option for relieving dysmenorrhea, especially when COC is not a favorable choice.

scholarly journals A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Giovani Missio ◽  
Doris Hupfeld Moreno ◽  
Frederico Navas Demetrio ◽  
Marcio Gerhardt Soeiro-de-Souza ◽  
Fernando dos Santos Fernandes ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Valproic Acid ◽  
Side Effects ◽  
Repeated Measures ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Young Patients ◽  
Similar Efficacy ◽  
Open Label

Abstract Background Treatment of bipolar disorder (BD) usually requires drug combinations. Combinations of lithium plus valproic acid (Li/VPA) and lithium plus carbamazepine (Li/CBZ) are used in clinical practice but were not previously compared in a head-to-head trial. Objective The objective of this trial was to compare the efficacy and tolerability of Li/VPA versus Li/CBZ in treating type 1 BD in any phase of illness in young individuals. Methods LICAVAL was a randomized, unicenter, open-label, parallel-group trial that was conducted from January 2009 to December 2012 in a tertiary hospital in São Paulo, Brazil. Participants were between 18 and 35 years old and were followed up for 2 years. Our primary outcome was the number of participants achieving/maintaining response and remission during the acute and maintenance phases of BD treatment, respectively. Other outcomes assessed were symptom severity and adverse events throughout the study. In the analysis of the primary outcome, we compared groups by using a two-way repeated measures analysis of variance and estimated effect sizes by using Cohen’s d. Results Of our 64 participants, 36 were allocated to Li/VPA and 28 to Li/CBZ. Our sample was composed predominantly of females (66.6%) and the average age was 27.8 years. A total of 27 (45.0%) participants had depression, 17 (28.3%) had mania/hypomania, and 16 (26.7%) had a mixed state. We found no between-group differences in CGI-BP (Clinical Global Impression Scale modified for use in bipolar disorder) scores (P = 0.326) or in any other outcome. Side effects differed significantly between groups only in the first week of treatment (P = 0.021), and there were more side effects in the Li/VPA group. Also, the Li/VPA group gained weight (+2.1 kg) whereas the Li/CBZ group presented slight weight loss (−0.2 kg). Conclusion Our study suggests that Li/VPA and Li/CBZ have similar efficacy and tolerability in BD but that Li/CBZ might have metabolic advantages in the long term. Trial registration ClinicalTrials.gov identifier: NCT00976794. Registered on September 9, 2009.

Biperiden and Haloperidol Plasma Levels and Extrapyramidal Side Effects in Schizophrenic Patients

1997 ◽  
Vol 36 (2) ◽  
pp. 69-72 ◽  
Author(s):  
Kurt Meszaros ◽  
Elisabeth Lenzinger ◽  
Kurt Hornik ◽  
Georg Schönbeck ◽  
Reinhold Hatzinger ◽  
...  
Keyword(s):  
Side Effects ◽  
Plasma Levels ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients
Sign in / Sign up

Export Citation Format

Share Document